Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2019 | Real world data for CD19 CAR-T in lymphoma patients in England

Claire Roddie • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma CAR-T

Claire Roddie, MD, PhD, University College London, London, United Kingdom, discusses real world data for relapsed/refractory high-grade lymphoma patients treated with CD19 CAR-T in England. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Claire Roddie

CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
17:12
CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more
Claire Roddie • 11 Apr 2025
Insights into the UCL CAR T program
1:28
Insights into the UCL CAR T program
Claire Roddie • 3 Jun 2023
Updates in ALL
Updates in ALL
Claire Roddie • 12 May 2023
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
3:38
Mechanisms of resistance to CAR-T in ALL: T-cell fitness, antigen loss and immunological rejection
Claire Roddie • 3 Jun 2023

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Claire Roddie • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Claire Roddie • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Claire Roddie • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Claire Roddie • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals